The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of
patients with cardiovascular disease. However, recurrent ischemic event occurrence during …

Clopidogrel is a widely-used antiplatelet drug. It is important for the treatment and prevention
of coronary heart disease. Clopidogrel can effectively reduce platelet activity and therefore …

Objectives: The purpose of the study was to systematically evaluate the significance of
platelet reactivity on clopidogrel treatment on adverse cardiovascular events using a …

Context High residual platelet reactivity (HRPR) in patients receiving clopidogrel has been
associated with high risk of ischemic events after percutaneous coronary intervention (PCI) …

Intense investigation continues on the pathobiology of stent thrombosis (ST) because of its
morbidity and mortality. Because little advance has been made in outcomes following ST …

Background—The clinical impact of platelet aggregation assessed by point-of-care assays is
unknown. We sought to evaluate whether high residual platelet reactivity (RPR) to ADP …

Platelets play a fundamental role in normal hemostasis, while their inherited or acquired
dysfunctions are involved in a variety of bleeding disorders or thrombotic events. Several …

In the normal course of the delivery of care, anesthesiologists encounter many patients who
are receiving drugs that affect platelet function as a fundamental part of primary and …

Oral antiplatelet drugs are a cornerstone of modern pharmacotherapy in cardiovascular
atherothrombotic diseases. The efficacy of acetylsalicylic acid (ASA, aspirin) and clopidogrel …

Aspirin is integral to the secondary prevention of cardiovascular disease and acts to impair
the development of platelet-mediated atherothromboembolic events by irreversible inhibition …